Krystal Biotech (KRYS) Net Margin (2021 - 2025)
Historic Net Margin for Krystal Biotech (KRYS) over the last 4 years, with Q3 2025 value amounting to 81.15%.
- Krystal Biotech's Net Margin rose 487500.0% to 81.15% in Q3 2025 from the same period last year, while for Sep 2025 it was 53.3%, marking a year-over-year increase of 316300.0%. This contributed to the annual value of 30.69% for FY2024, which is 91300.0% up from last year.
- As of Q3 2025, Krystal Biotech's Net Margin stood at 81.15%, which was up 487500.0% from 39.91% recorded in Q2 2025.
- Krystal Biotech's 5-year Net Margin high stood at 1059.79% for Q1 2021, and its period low was 2.06% during Q1 2024.
- In the last 4 years, Krystal Biotech's Net Margin had a median value of 40.19% in 2025 and averaged 229.23%.
- Per our database at Business Quant, Krystal Biotech's Net Margin tumbled by -9113400bps in 2024 and then skyrocketed by 487500bps in 2025.
- Quarter analysis of 4 years shows Krystal Biotech's Net Margin stood at 1059.79% in 2021, then plummeted by -98bps to 20.62% in 2023, then skyrocketed by 142bps to 49.95% in 2024, then soared by 62bps to 81.15% in 2025.
- Its Net Margin stands at 81.15% for Q3 2025, versus 39.91% for Q2 2025 and 40.47% for Q1 2025.